Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-02
2010-11-30
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S279000, C546S115000, C546S118000, C514S302000, C514S303000
Reexamination Certificate
active
07842698
ABSTRACT:
The present invention relates to pyridine methylene azolidinone compounds of Formula (I)for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, allergy, asthma, pancreatitis, multi-organ failure, kidney diseases, platelet aggregation, cancer, sperm motility, graft rejection or lung injuries. Specifically, the present invention is related to pyridine methylene azolidinone derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide-3-kinases, PI3Ks.
REFERENCES:
patent: 2007/0021447 (2007-01-01), Rueckle et al.
patent: 2007/0155776 (2007-07-01), Betschmann et al.
patent: 2009/0028855 (2009-01-01), Cheng et al.
patent: 2009/0082357 (2009-03-01), Fitch et al.
patent: 2009/0099172 (2009-04-01), Cai et al.
patent: 2004 007491 (2004-01-01), None
patent: 2004 052373 (2004-06-01), None
patent: 2004 056820 (2004-07-01), None
Wikipedia, Phosphoinositide 3-kinase, http://en.wikipedia.org/wiki/Phosphoinositide—3-kinase, downloaded Dec. 31, 2009.
Shunsaku Shiotani, et al., “Furopyridines. XXII ′1!. Elaboration of the C-Substituents Alpha to the Heteronitrogen Atom of Furo ′2, 3-b!-, ′3, 2-b!-, ′2, 3-c!- and ′3, 2-c! Pyridine”, J. Heterocyclic Chem., vol. 34, XP 002313138, pp. 901-907, 1997.
Malvinder P. Singh, et al., “Synthesis and Sequence-Specific DNA Binding of a Topoisomerase Inhibitory Analog of Hoechst 33258 Designed for Altered Base and Sequence Recognition”, Chemical Research in Toxicology, vol. 5, No. 5, XP 002066288, pp. 597-607, 1992.
Kay M. Brummond, et al., “Solid-Phase Synthesis of BRL 49653”, J. Org. Chem. vol. 64, pp. 1723-1726, 1999.
Lewis C. Cantley, “The Phosphoinoisitide 3-Kinase Pathway”, Science, vol. 296, pp. 1655-1657, 2002.
M. P. Cava, et al., “Pyridine Derivatives. III. The Rearrangement of Some Simple 3-Halopyridine-N-Oxides”, J. Org. Chem., vol. 23, pp. 1616-1617, 1958.
Jin Soon Cha, et al., “Exceptionally Facile Reduction of Acid Chlorides to Aldehydes by Sodium Tri-Tert-Butoxyaluminohydride”, J. Org. Chem., vol. 58, No. 17, pp. 4732-4734, 1993.
J. D. Fraser, et al., “Regulation of Interleukin-2 Gene Enhancer Activity”, Science, vol. 251, pp. 313-316, 1991.
David A. Fruman, et al., “Phosphoinositide Kinases”, Annu. Rev. Biochem. vol. 67, pp. 481-507, 1998.
Graig Gerard, et al., “Chemokines and Disease”, Nature Immunology, vol. 2, No. 2, pp. 108-115, 2001.
Steven Grant, “Targeted Therapies in Cancer- Second International Congress”, IDrugs, vol. 6, No. 10, pp. 946-948, 2003.
Emilio Hirsch, et al., “Central Role for G Protein-Coupled Phosphoinositide 3-Kinase γ in Inflammation”, Science, vol. 287, pp. 1049-1053, 2000.
Emilio Hirsch, et al., “Resistance to Thromboembolism in PI3Kγ-Deficient Mice”, The FASEB Journal, vol. 15, No. 11, pp. 2019-2021, 2001.
Roy Katso, et al. “Cellular Function of Phosphoinositide 3-Kinases: Implications for Development, Immunity, Homeostasis, and Cancer”, Annu. Rev. Cell Dev. Biol., vol. 17, pp. 615-675, 2001.
Muriel Laffargue, et al., “Phosphoinositide 3-Kinase γ is an Essential Amplifier of Mast Cell Function”, Immunity, vol. 16, No. 3, pp. 441-451, 2002.
Margaret A. Lawlor, et al., “PKB/AKT: A Key Mediator of Cell Proliferation, Survival and Insulin Reponses”, Journal of Cell Science, vol. 114, No. 16, pp. 2903-2910, 2001.
Nick R. Leslie, et al., “Phosphoinositide-Regulated Kinases and Phosphoinositide Phosphatases”, Chem. Rev. vol. 101, No. 8, pp. 2365-2380, 2001.
Marco Lopez-Ilasaca, et al., “Phosphoinositide 3-Kinase γ is a Mediator of Gβγ-Dependent Jun Kinase Activation”, The Journal of Biological Chemistry, vol. 273, No. 5, pp. 2505-2508, 1998.
Francoise Pages, et al., “Binding of Phosphatidylinositol- 3-OH Kinase to CD28 Is Required for T-Cell Signalling”, Nature, vol. 369, pp. 327-329, 1994.
Peter J. Parker, “PI 3-Kinase Puts GTP on the RAC”, Current Biology, vol. 5, No. 6, pp. 577-579, 1995.
Ananthachari Srinivasan , et al., “Pyridopyrimidines. 10. Nucleophilic Substitutions in the Pyrido [3, 2-d] Pyrimidine Series”, J.Org. Chem. vol. 44, No. 3, pp. 435-440, 1979.
Robert C. Stein, et al., “PI3-Kinase Inhibition: A Target for Drug Development?”, Molecular Medicine Today, vol. 6, No. 9, pp. 347-357, 2000.
Lens Stephens, et al., “Roles of PI3KS in Leukocyte Chemotaxis and Phagocytosis”, Current Opinion Cell Biology, vol. 14, No. 2, pp. 203-213, 2002.
Marcus Thelen, et al., “Wortmannin Binds Specifically to 1-Phosphatidylinositol 3-Kinase While Inhibiting Guanine Nucleotide-Binding Protein-Coupled Receptor Signaling in Neutrophil Leukocytes”, Proc. Natl. Acad. Sci. USA, vol. 91, pp. 4960-4964, 1994.
Lutz F. Tietze, et al., “The Knoevenagel Reaction”, Pergamon Press, Oxford, Eds.: Trost B. M. Fleming I, pp. 341-394, 1991.
A. Toker, “Phosphoninositides and Signal Transduction”, CMLS Cellular and Molecular Life Sciences, vol. 59, No. 5, pp. 761-779, 2002.
Bart Vanhaesebroeck, et al., “Synthesis and Function of 3-Phosphorylated Inositol Lipids”, Annu. Rev. Biochem., vol. 70, pp. 535-602, 2001.
Bart Vanhaesebroeck, et al., “Phosphoinositide 3-Kinases: A Conserved Family of Signal Transducers”, Trends Biochem. Sci., vol. 22, No. 7, pp. 267-272, 1997.
Matthias P. Wymann, et al., “Lipids on the Move: Phosphoinositide 3-Kinases in Leukocyte Function”, Trends Immunology Today, vol. 21, No. 6, pp. 260-264, 2000.
Ryoji Yao, et al., “Requirement for Phosphatidylinositol-3 Kinase in the Prevention of Apoptosis by Nerve Growth Factor”, Science, vol. 267, pp. 2003-2006, 1995.
R. N. P. Singh, et al., “Modified Forms of Human Growth Hormone With Increased Biological Activities”, American Cancer Society, vol. 94, No. 3, pp. 883-891, 1974.
Joseph B. Schwartz, “Pharmaceutical Manufacturing”, Part 5 of Remington's Pharmaceutical Sciences, 20th Edition, Marck Publishing Company, pp. 670-1050, 2000.
U.S. Appl. No. 12/469,092, filed May 20, 2009, Rueckle, et al.
Matthew J. Thomas, et al.; “Airway inflammation: chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases”; European Journal of Immunology; 2005; 35; pp. 1283-1291.
Montserrat Camps, et al.; “Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis”; Nature Medicine; Sep. 2005; vol. 11;No. 9; pp. 936-943.
Domingo F. Barber, et al.; “PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus”; Brief Communications; Nature Medicine; Sep. 2005; vol. 11; No. 9; pp. 933-935.
Carmine Vecchione, et al.; “Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kγ”; The Journal of Experimental Medicine; Apr. 18, 2005; vol. 201; No. 8; pp. 1217-1228.
Enrico Lupia, et al.; “Ablation of Phosphoinositide 3-kinase-γ Reduces the Severity of Acute Pancreatitis”; American Journal of Pathology; 2004; 165 (Abstract Only).
M. P. Wymann, et al.; “Phosphoinositide 3-kinaseγ: a key modulator in inflammation and allergy”; Biochemical Society; 2003; pp. 275-280.
Emilio Hirsch, et al.; “Resistance to thromboembolism in PI3Kγ—deficient mice1”; The FASEB Journal; Sep. 2001; vol. 15; pp. 2019-2021.
Ho-Kee Yum, et al.;“Involvement of Phosphoinositide 3-Kinases in Neutrophil Activation and the Development of Acute Lung Injury”; The American Association of Immunologists; 2001; pp. 6601-6608.
Enrico Patrucco, et al.; “PI3Kγ Modulates the Cardiac Response to Ch
Bischoff Alexander
Covini David
Dorbais Jerome
Pomel Vincent
Quattropani Anna
Jaisle Cecilia M
Merck Serono S.A.
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Wilson James O
LandOfFree
Pyridine methylene azolidinones and use thereof... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridine methylene azolidinones and use thereof..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridine methylene azolidinones and use thereof... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4230020